3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
3
Other hematologic neoplasm
2
Tumor-Agnostic
1
Myeloid
1
Genitourinary
1
Gastrointestinal
1
Classical hematology
1
Breast
1
Conditions
Esophageal Squamous Cell Carcinoma
1
Adenocarcinoma Of Esophagus
1
Interventions
Oxaliplatin
1004
Fluorouracil
800
Capecitabine
765
Gemcitabine
651
Leucovorin
559
Irinotecan
537
Bevacizumab
513
Radiotherapy
460
Cisplatin
441
Drug Therapy
298
Cetuximab
280
Surgical Procedures, Operative
229
Paclitaxel
228
S 1 (combination)
218
pembrolizumab
206
Docetaxel
199
130-nm albumin-bound paclitaxel
196
Nivolumab
193
sintilimab
191
Radiosurgery
190
lenvatinib
181
Folfox protocol
179
Sorafenib
178
Albumin-Bound Paclitaxel
173
apatinib
170
tislelizumab
161
camrelizumab
160
Neoadjuvant Therapy
158
Blood Specimen Collection
154
durvalumab
148
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
monalizumab
×
Gastrointestinal
×
Clear all
NCT03307941
2017-12-19
ARTEMIS-Eso
Jules Bordet Institute
Phase 1/2
Withdrawn